Abstract

Triple-negative breast cancer (TNBC) presents a marked diversity at the molecular level, which promotes a clinical heterogeneity that further complicates treatment. We performed a detailed whole exome sequencing profile of 29 Mexican patients with long follow-up TNBC to identify genomic alterations associated with overall survival (OS), disease-free survival (DFS), and pathologic complete response (PCR), with the aim to define their role as molecular predictive factors of treatment response and prognosis. We detected 31 driver genes with pathogenic mutations in TP53 (53%), BRCA1/2 (27%), CDKN1B (9%), PIK3CA (9%), and PTEN (9%), and 16 operative mutational signatures. Moreover, tumors with mutations in BRCA1/2 showed a trend of sensitivity to platinum salts. We found an association between deficiency in DNA repair and surveillance genes and DFS. Across all analyzed tumors we consistently found a heterogeneous molecular complexity in terms of allelic composition and operative mutational processes, which hampered the definition of molecular traits with clinical utility. This work contributes to the elucidation of the global molecular alterations of TNBC by providing accurate genomic data that may help forthcoming studies to improve treatment and survival. This is the first study that integrates genomic alterations with a long follow-up of clinical variables in a Latin American population that is an underrepresented ethnicity in most of the genomic studies.

Highlights

  • Breast cancer (BC) is the most prevalent and lethal cancer in women worldwide [1]

  • We looked for clinical trials on BC for approved treatments in other cancers that target the driver mutations detected in the three cohorts, and found 103 trials and 15 drugs tested (Trametinib, Vemurafenib, Crizotinib, Cetuximab, Panitumumab, Afatinib, Gefitinib, Erlotinib, Tretinoin, Imatinib, Sunitinib, Ruxolitinib, Dasatinib, Bosutinib, Everolimus) (Table S5)

  • Program (SEER) database showed that the Overall survival (OS) of stage III triple-negative breast cancer (TNBC) was

Read more

Summary

Introduction

Breast cancer (BC) is the most prevalent and lethal cancer in women worldwide [1] It is clinically classified by the presence or absence of hormone receptors (estrogen receptor (ER) and progesterone receptor (PR)) and human epidermal growth factor receptor type 2 (HER2), which define the cancer subtype: Hormone-positive, HER2 positive, or triple-negative (TNBC). This classification is the gold standard procedure to decide the standard in each patient [2]. Targeted treatments such as trastuzumab, aromatase inhibitors, or selective hormonal receptor modulators have significantly improved the response and overall survival (OS) [3]. TNBC has a faster proliferation rate, higher histological grade, and a variable degree of tumor-infiltrating lymphocytes, which make these tumors more aggressive and the most associated by far with mortality among the three subtypes of BC [4]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call